The past, present and future of study in the chemotherapy of drug-resistant tuberculosis

doi:10.3969/j.issn.1000-6621.2014.08.003

Abstract

Abstract: The prevalence of drug-resistant tuberculosis (TB) is one of the main challenges on current TB control which seriously influences the achievement people had made in this field. Anti-TB drugs are the most effective weapons in controlling TB, however, they have been obviously not enough to deal with multidrug-resistant TB, especially extensively drug-resistant TB, TB is more likely to become the incurable disease again because of this reason. Therefore, it is urgent to develop more effective anti-TB drugs, design the chemotherapy regiment on drug-resistant TB and solve the difficulty in treating drug-resistant TB. The authors reviewed the history, focused on the present and looked ahead the future, elucidated several issues about treatment on drug-resistant TB and had expectation that readers would have a comprehensively understanding of chemotherapy for drug-resistant TB and make efforts altogether to explore the possibility of controlling the epidemic of drug-resistant TB by chemotherapy.

Key words: Tuberculosis, multidrug-resistant/drug therapy, Clinical protocols, Retrospective studies

XIAO He-ping, FANG Yong, FAN Lin, LIU Yi-dian. The past, present and future of study in the chemotherapy of drug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis, 2014, 36(8): 634-637. doi: 10.3969/j.issn.1000-6621.2014.08.003

References

［1］Grosset J.The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy.Bull Int Union Tuberc, 1978，53(1):5-12.
［2］［No authors listed］.Controlled clinieal trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet,1974, 2(7875):237-240.
［3］World Health Organization.Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210. Geneva:World Health Organization,1996.
［4］World Health Organization．Global tuberculosis report 2013. Geneva：World Health Organization，2013．
［5］Sbarbaro JA, Iseman MD, Crowle AJ. Combined effect of pyrazinamide and ofloxacin within the human macrophage.Tuber Lung Dis, 1996, 77(6):491-495.
［6］中国防痨协会. 耐多药结核病化学治疗的意见(试行). 中国防痨杂志，2003，25 (1)：4-9.
［7］中国防痨协会. 耐多药结核病化学治疗指南（2009）.中国防痨杂志，2010，32（4）：181-198.
［8］World Health Organization. Guidelines for the programmaticmanagement of drug-resistant tuberculosis. 2011 update.WHO/HTM/TB/2011.6. Geneva: World Health Organization, 2011.
［9］Sullivan EA，Kreiswirth BN，Palumbo L，et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City．Lancet，1995，345(8958)：1148-1150．
［10］肖和平.耐多药结核病化疗药物的选择与方案的制定.中华结核和呼吸杂志，2006,29(8):517-519.
［11］World Health Organization. Guidelines for the programmaticmanagement of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: World Health Organization, 2006.
［12］吴惠忠，尹建军，钟耐容，等. 广东省全球基金耐多药结核病项目阶段性实施情况分析.中国防痨杂志, 2013,35(10): 799-802.
［13］唐神结，肖和平. 利奈唑胺抗结核作用的研究及其最新进展. 中华临床医师杂志(电子版)，2010，4（1）：63-66．
［14］中国防痨协会结核病临床专业委员会.结核病临床诊治进展年度报告（2012年）（第二部分结核病临床治疗）.中国防痨杂志,2013,35(7):488-510.
［15］Nuermberger EL，Spigelman MK，Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology,2010,15(5)：764-778.
［16］Ma Z，Lienhardt C，McIlleron H，et al．Global tuberculosis drug development pipeline: the need and the reality.Lancet，2010，375（9731）：2100-2009.
［17］Diacon AH，Donald PR，Pym A，et al．Randomized pilot trial of eight weeks of bedaquiline（TMC207） treatment for multidrug-resistant tuberculosis：long-term outcome，tolerability，and effect on emergence of drug resistance. Antimicrob Agents Chemother,2012,56(6):3271-3276.
［18］Gler MT，Skripconoka V，Sanchez-Garavito E，et al．Delamanid for multidrug-resistant pulmonary tuberculosis．N Engl J Med, 2012, 366(23):2151-2160．
［19］Skripconoka V，Danilovits M，Pehme L，et al．Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J,2013，41(6)：1393-1400．
［20］World Health Organization.Joint meeting of the global GLC Committee and the MDR-TB Core Group.Geneva: World Health Organization, 2013.
［21］Cox H，Ford N．Linezolid for the treatment of complicated drug-resistant tuberculosis：a systematic review and meta ana-lysis．Int J Tuberc Lung Dis，2012，16（4）:447-454．
［22］Rosenthal IM,Zhang M，Williams KN，et al．Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med, 2007,4(12):e344．

[1]	Qiu Yong, Quan Zhuo, Qu Rong, Tian Fajun, Li Meng, Wang Gengsheng, Wang Ya, Guo Mingcheng, Gao Qian. Evaluation of different tuberculosis diagnostic tools for detecting patients in a primary-level clinic in rural China: a real-world retrospective study [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 181-188.
[2]	Li Yang, Sun Feng, Zhang Wenhong. Short-course treatment for tuberculosis: past achievements and future directions [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 991-997.
[3]	Wang Xueyu, Shi Wenhui, Li Qi, Jing Wei, Chu Naihui, Nie Wenjuan. Efficacy and safety of Baidiziyin Pill and Shenqiyifei Pill in adjuvant treatment of susceptible pulmonary tuberculosis patients: a national randomized controlled multicenter clinical study [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1306-1312.
[4]	Fu Liang, Deng Guofang. MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 18-22.
[5]	Zhao Jiawen, Zhang Yongzhong, Li Zhenhua, Mao Yicheng, Zhang Jingjing, Hu Chengyang, Zhang Xiujun, Kan Xiaohong. Effects of air pollutants and greenness exposure on the mortality of newly treated tuberculosis patients in three cities, Anhui Province [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 75-84.
[6]	Ding Qin, Zhang Shengkang, Ren Fei, Chen Xiaohong, Hu Chunmei, Chen Wei, Fan Lin. Nutritional status of drug-resistant pulmonary tuberculosis patients and the influencing factors: a multi-center, large-sample study [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 826-832.
[7]	Ding Qin, Chen Wei, Zhang Shengkang, Ren Fei, Chen Xiaohong, Hu Chunmei, Chen Danping, Fan Lin. Investigation of nutritional status and analysis of influencing factors in patients with extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 839-844.
[8]	Wu Tana, Li Yuhong, Liu Xiaoqiu. Study on the feasibility of active tuberculosis screening strategy for the elderly based on public health service [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 372-376.
[9]	Zhou Feng, Li Tongxin, Yang Song, Tang Shenjie. Progress on short-course regimens for the treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 311-317.
[10]	Ge Qiping, Zhang Lijie, Huang Xuerui, Jiang Guanglu, Han Xiqin, Wang Jingping, Du Jian, Ma Yan, Gao Weiwei. Effect of a new treatment regimen on patients with initially retreated drug-sensitive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1078-1083.
[11]	Gao Dan, Wang Linghua, Huang Jinpeng, Zhang Yue, Mao Xiaoxiao. Construction of pulmonary rehabilitation nursing program of integrated traditional Chinese and Western medicine for patients with tuberculous empyema under thoracoscopic clearance [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 932-939.
[12]	Gao Dan, Wang Linghua, Huang Jinpeng, Zhang Yue, Mao Xiaoxiao. Analysis of the application effect of integrated traditional Chinese and Western medicine pulmonary rehabilitation nursing program for patients with tuberculous empyema undergoing thoracoscopic clearance [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 940-948.
[13]	Wang Yuxiang, Chen Qiuqi, Yu Xinxin, Zhan Senlin, Zhang Peize, Deng Guofang. 3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection:a prospective study [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 906-910.
[14]	Xie Jingyi, Zou Ruifeng, Chen Yulan, Chen Yong, Liu Dongzhou, Hong Xiaoping. Analysis of clinical features and peripheral lymphocyte subsets of systemic lupus erythematosus patients complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 911-916.
[15]	Zhou Qian, Deng Guofang, Wang Qingwen. Retrospective analysis of clinical intervention and follow-up of patients with systemic lupus erythematosus complicated with tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1294-1302.